ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 70 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,171,250 | +11.4% | 1,325,000 | 0.0% | 1.77% | +15.8% |
| Q2 2023 | $13,621,000 | +33.2% | 1,325,000 | 0.0% | 1.53% | -1.7% |
| Q1 2023 | $10,229,000 | +104931.3% | 1,325,000 | 0.0% | 1.56% | +6.1% |
| Q4 2022 | $9,739 | -99.9% | 1,325,000 | 0.0% | 1.47% | -4.3% |
| Q3 2022 | $9,540,000 | – | 1,325,000 | – | 1.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 4,708,288 | $42,233,000 | 12.94% |
| Lynx1 Capital Management LP | 1,484,693 | $13,318,000 | 12.36% |
| Omega Fund Management, LLC | 2,029,580 | $18,205,000 | 3.73% |
| TCG Crossover Management, LLC | 1,034,222 | $9,277,000 | 3.72% |
| Frazier Life Sciences Management, L.P. | 4,185,757 | $37,546,000 | 3.20% |
| Paradigm Biocapital Advisors LP | 336,229 | $3,016,000 | 0.80% |
| Orbimed Advisors | 4,081,592 | $36,612,000 | 0.59% |
| BVF INC/IL | 1,589,495 | $14,258,000 | 0.57% |
| Kingsbury Capital Investment Advisors LLC | 29,153 | $262,000 | 0.29% |
| Avidity Partners Management LP | 1,207,000 | $10,827,000 | 0.22% |